Anzeige
Mehr »
Samstag, 18.04.2026 - Börsentäglich über 12.000 News
Deutliche Überlegenheit der Erzgehalte: Die Zahlen lügen nicht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PV0Q | ISIN: CA87975M2085 | Ticker-Symbol: 3D0A
Frankfurt
17.04.26 | 15:36
0,026 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TELO GENOMICS CORP Chart 1 Jahr
5-Tage-Chart
TELO GENOMICS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0330,03817.04.
0,0340,03817.04.

Aktuelle News zur TELO GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrTelo Genomics Corp (2): Telo Genomics debenture private placement3
DiTelo Genomics Corp (2): Telo Genomics launches myeloma relapse risk study6
DiTelo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma129Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and...
► Artikel lesen
31.03.Telo Genomics Corp (2): Telo Genomics appoints Farlinger as CEO, chairman5
31.03.Telo Genomics appoints John Farlinger as CEO2
31.03.Telo Genomics Corp.: Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman253Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and...
► Artikel lesen
09.03.Telo Genomics Corp (2): Telo Genomics closes debenture financing2
09.03.Telo Genomics Corp.: Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing184Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and...
► Artikel lesen
TELO GENOMICS Aktie jetzt für 0€ handeln
28.02.Telo Genomics Corp (2): Telo Genomics increases private placement to $1.6M2
27.02.Telo Genomics stockt Privatplatzierung von Wandelanleihen auf 1,6 Mio. $ auf5
27.02.Telo Genomics increases convertible debenture offering to $1.6M1
27.02.Telo Genomics Corp.: Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement407Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic...
► Artikel lesen
18.02.Telo Genomics Corp (2): Telo Genomics closes first tranche for $840,0003
18.02.Telo Genomics Corp.: Telo Genomics Closes First Tranche of Convertible Debentures Financing188THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp....
► Artikel lesen
29.01.Telo Genomics Corp.: Telo Genomics Announces Appointment of John Price as Chief Financial Officer204Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic...
► Artikel lesen
20.01.Telo Genomics Corp (2): Telo Genomics arranges $1.2-million debenture financing2
19.01.Telo Genomics kündigt Privatplatzierung von Wandelanleihen über 1,2 Millionen Dollar an7
19.01.Telo Genomics announces $1.2 million convertible debenture offering1
19.01.Telo Genomics Corp.: Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000329THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESToronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO)...
► Artikel lesen
18.12.25Telo Genomics Corp.: Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program663Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,21